Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of “Moderate Buy” from Brokerages
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price […]
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price […]
